The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Trial Profile

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Macitentan (Primary) ; Selexipag (Primary) ; Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TRITON
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 08 Sep 2017 Planned number of patients changed from 144 to 238.
    • 08 Sep 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 08 Sep 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top